Preclinical study demonstrates engineered extracellular vesicles suppress ferroptosis and restore redox balance in nucleus pulposus cells, indicating therapeutic potential for disc degeneration.
Intervertebral disc degeneration (IDD) is driven by ferroptosis of nucleus pulposus cells (NPCs) as a core pathological mechanism. Nucleus pulposus progenitor cells (NPPCs), exhibiting stem cell-like properties, yield extracellular vesicles (PEVs) with high affinity for NPCs and enable targeted phenotypic regulation. However, natural PEVs possess limited bioactivity. Therefore, we constructed engineered mFD-PEVs modified with FTH1 and DAB2. In vitro experiments demonstrated that mFD-PEVs efficiently deliver FTH1, maintained SLC7A11/GPX4-associated redox defense, suppress NPCs oxidative stress, and attenuate ferroptosis. Furthermore, in vivo studies confirmed the potent therapeutic efficacy of mFD-PEVs in promoting intervertebral disc regeneration. Transcriptomic analysis further revealed that mFD-PEVs predominantly modulate molecular pathways associated with ferroptosis and oxidative stress. In summary, the gene-edited mFD-PEVs reprogram redox homeostasis in NPCs, regulate ferroptosis, and promote intervertebral disc regeneration.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: